However, in more advanced tumor stages, because of elevated CSF2 and IFN-γ levels in the TME, they start expressing PD-L1 and acquire an immunosuppressive phenotype, leading to worse prognoses for cancer patients [85,88,89]. The gene discussed is CSF2; the disease is neoplasm.